We are delighted to announce that its 4th annual
ADC Summit 2015 conference will take place on 18th - 19th May in London, UK.
Recent clinical successes have generated intense interest in
ADC therapeutics. To develop
ADCs that are more specific, more stable, and more effective; continued optimisation of the antibody, linker and payload of an
ADC is critical.
This conference goes to the heart of the technological challenges and asks:
What does it take to develop superior
ADCs and gain the clinical edge?
Join us as we share, confer and debate how to create the next wave of
ADCs with better efficacy, lower toxicity and improved potency for clinical success.
Benefits of Attending
- Hear more about the payload developments
- Updates of ADCs in clinical trials
- Learn more about biodistribution and tumour penetrations
- Aim for improvement of the therapeutic index
- Discover strategies for effective targeting and managing ADC off-target toxicities
- Understand the status of the development of novel binding moieties
- Innovations in linker technologies
Plus an Interactive Half-Day Post-Conference Workshop | Wednesday 20th May 2014
ADCs: A Journey Through DevelopmentWorkshop leaders: Dr Richard Turner, Principal Consultant, Natalie Thomas, Consultant, Simon Bishop, Associate Consultant, BioDesk
8.30am - 12.30pm
Speakers
- Angela Romanelli, Senior Director, Biomarkers, ImmunoGen, Inc.
- Carlo Boutton, Director of Technology, Ablynx
- Chris Scott, Chair of Pharmaceutical Biosciences, Queens University Belfast
- Christophe Bonny, Chief Scientific Officer, Bicycle Therapeutics Limited
- Christopher P Leamon, Vice President of Research, Endocyte, Inc.
- David E. Thurston, Professor of Drug Discovery, Kings College University
- Erica Hong, Scientist, ImmunoGen, Inc.
- Giulio Casi, Head of Targeted Cytotoxics Development, Philochem AG
- Iontcho Vlahov, Vice President of Discovery Chemistry, Endocyte, Inc.
- James Legg, Patent Attorney, Boult Wade Tennant
- Justin Mason-Home, Managing Director, SafeBridge Europe, Limited
- Klaus Bosslet, Head Discovery Oncology, Pharma Research & Early Development, Roche Innovation Center Penzberg
- Luke Masterson, Chemistry Group Leader, Spirogen
- Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.
- Marc Robillard, CEO, Tagworks Pharmaceuticals
- Michael Webb, Associate Professor, University of Leeds
- Natalie Thomas, Consultant, Clinical Network Services (UK) Ltd
- Peter Bach, Director, BioPharmaLogic Ltd.
- Roger Beerli, Vice President Research & Development, NBE-Therapeutics AG
- Vijay Chudasama, Research Associate, University College London
The full agenda is not yet available for this event.
Follow this event to receive an alert when the agenda becomes available.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Who should attend
Chief Scientific Officer, Heads/Vice Presidents of Drug Discovery, CEO, Senior Scientist, Principal Scientists with responsibility in the following departments:-
- Drug Discovery
- Biologics
- Biologics generation
- Antibody research
- Antibody conjugate development
- Antibody conjugate discovery
- Biomelecular Research
- Genomics Research
- Antibody Engineering
- Protein Sciences
- Protein Technologies
- Bioanalyticcs
- Cell Assays
- Molecular Cell Biology
- Drug Discovery Pharamacology
- Regulatory Affairs
- CMC
- Biotherapeutics
- In Vitro Platfroms
- Antibody and vaccine leads
- Monoclonal Antibody
- Oncology
- Molecular and Translational Medicine
- Tumor Virology
Venue
Holiday Inn London BloomsburyCoram Street
London, WC1N 1HT
United Kingdom
